Literature DB >> 31736141

Factor structure of the Montreal Cognitive Assessment in Parkinson disease.

Callum R Smith1, Jonathan Cavanagh2, Matthew Sheridan3, Katherine A Grosset4, Breda Cullen2, Donald G Grosset4.   

Abstract

OBJECTIVES: The Montreal Cognitive Assessment (MoCA) is a common tool for screening mild cognitive impairment (MCI) and dementia. Studies in multiple clinical groups provide evidence for various factor structures mapping to different cognitive domains. We tested the factor structure of the MoCA in a large cohort of early Parkinson disease (PD).
MATERIALS AND METHODS: Complete MoCA data were available from an observational cohort study for 1738 patients with recent-onset PD (64.6% male, mean age 67.6, SD 9.2). Confirmatory factor analysis (CFA) was applied to test previously defined two-factor, six-factor, and three-factor models in the full sample and in a subgroup with possible cognitive impairment (MoCA < 26). Secondary analysis used exploratory factor analysis (EFA; principal factors with oblique rotation).
RESULTS: The mean MoCA score was 25.3 (SD 3.4, range 10-30). Fit statistics in the six-factor model (χ2 /df 17.77, root mean square error of approximation [RMSEA] 0.10, comparative fit index [CFI] 0.74, Tucker-Lewis index [TLI] 0.69, standardised root mean square residual [SRMR] 0.07) indicated poorer fit than did previous studies. Findings were similar in the two-factor and three-factor models. EFA suggested an alternative six-factor solution (short-term recall, visuospatial-executive, attention/working memory, verbal-executive, orientation, and expressive language), although CFA did not support the validity of the new model.
CONCLUSIONS: The factor structure of the MoCA in early PD was not consistent with that of previous research. This may reflect higher cognitive performance and differing demographics in our sample. The results do not support a clear, clinically relevant factor structure in an early PD group, suggesting that the MoCA should be followed with detailed assessment to obtain domain-specific cognitive profiles.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Parkinson disease/psychology; cognition disorders/psychology; factor analysis, statistical; mental status and dementia tests; neuropsychological tests; psychometrics

Mesh:

Year:  2019        PMID: 31736141     DOI: 10.1002/gps.5234

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  3 in total

1.  Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.

Authors:  Patrick J Smith; Meagan Lew; Yen Lowder; Kristi Romero; Jillian C Thompson; Lauren Bohannon; Alyssa Pittman; Alexandra Artica; Sendhilnathan Ramalingam; Taewoong Choi; Cristina Gasparetto; Mitchell Horwitz; Gwynn Long; Richard Lopez; David Rizzieri; Stefanie Sarantopoulos; Keith Sullivan; Nelson Chao; Anthony D Sung
Journal:  Bone Marrow Transplant       Date:  2021-10-19       Impact factor: 5.483

2.  The Need for a Specialized Neurocognitive Screen and Consistent Cognitive Impairment Criteria in Spinal Cord Injury: Analysis of the Suitability of the Neuropsychiatry Unit Cognitive Assessment Tool.

Authors:  Danielle Sandalic; Yvonne Tran; Ashley Craig; Mohit Arora; Ilaria Pozzato; Grahame Simpson; Bamini Gopinath; Jasbeer Kaur; Sachin Shetty; Gerard Weber; Lisa Benad; James W Middleton
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

3.  Association of ATG5 gene polymorphism with Parkinson's disease in a Han Chinese population.

Authors:  Jing Han; Ganghua Feng; Jibao Wu; Yi Zhang; Zhipeng Long; Xiaoxi Yao
Journal:  Acta Neurol Belg       Date:  2021-10-18       Impact factor: 2.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.